Alterity Therapeutics Ltd. (AU:ATH) has released an update.
Alterity Therapeutics has announced promising new findings for ATH434, which shows potential in treating the rare neurodegenerative disorder Friedreich’s Ataxia by acting as an iron chaperone to redistribute toxic iron within the body. Unlike traditional iron chelators, ATH434 specifically targets pathogenic ferrous iron, potentially slowing disease progression without hampering normal iron functions. These developments have sparked interest in ATH434 as a treatment for other neurodegenerative diseases, with ongoing clinical trials for Parkinsonian disorders.
For further insights into AU:ATH stock, check out TipRanks’ Stock Analysis page.
